Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol
Blood Pressure, Volume 30, No. 5, Year 2021
Notification
URL copied to clipboard!
Description
Background: Hypertension and diabetes cause chronic kidney disease (CKD) and diastolic left ventricular dysfunction (DVD) as forerunners of disability and death. Home blood pressure telemonitoring (HTM) and urinary peptidomic profiling (UPP) are technologies enabling prevention. Methods: UPRIGHT-HTM (Urinary Proteomics Combined with Home Blood Pressure Telemonitoring for Health Care Reform [NCT04299529]) is an investigator-initiated 5-year clinical trial with patient-centred design, which will randomise 1148 patients to be recruited in Europe, sub-Saharan Africa and South America. During the whole study, HTM data will be collected and freely accessible for patients and caregivers. The UPP, measured at enrolment only, will be communicated early during follow-up to 50% of patients and their caregivers (intervention), but only at trial closure in 50% (control). The hypothesis is that early knowledge of the UPP risk profile will lead to more rigorous risk factor management and result in benefit. Eligible patients, aged 55–75 years old, are asymptomatic, but have ≥5 CKD- or DVD-related risk factors, preferably including hypertension, type-2 diabetes, or both. The primary endpoint is a composite of new-onset intermediate and hard cardiovascular and renal outcomes. Demonstrating that combining UPP with HTM is feasible in a multicultural context and defining the molecular signatures of early CKD and DVD are secondary endpoints. Expected outcomes: The expected outcome is that application of UPP on top of HTM will be superior to HTM alone in the prevention of CKD and DVD and associated complications and that UPP allows shifting emphasis from treating to preventing disease, thereby empowering patients. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Authors & Co-Authors
Thijs, Lutgarde B.
Belgium, Leuven
Ku Leuven
Asayama, Kei
Japan, Tokyo
Teikyo University School of Medicine
Japan, Sendai
Tohoku Institute for Management of Blood Pressure
Belgium, Mechelen
Research Institute Alliance for the Promotion of Preventive Medicine
Maestre, Gladys E.
Belgium, Mechelen
Research Institute Alliance for the Promotion of Preventive Medicine
Hansen, Tine Willum
Belgium, Mechelen
Research Institute Alliance for the Promotion of Preventive Medicine
Denmark, Herlev
Steno Diabetes Center Copenhagen
Buyse, Luk
Belgium, Brussels
Vrije Universiteit Brussel
Wei, Dongmei
Belgium, Leuven
Ku Leuven
Melgarejo, Jesus D.
Belgium, Leuven
Ku Leuven
Brguljan-Hitij, Jana
Slovenia, Ljubljana
Univerzitetni Klinični Center Ljubljana
Cheng, Haoming
Taiwan, Taipei
Taipei Veterans General Hospital
de Souza, Fabio
Brazil, Rio de Janeiro
Universidade Federal do Estado do Rio de Janeiro
Gilis-Malinowska, Natasza
Poland, Gdansk
Gdanski Uniwersytet Medyczny
Kawecka-Jaszcz, Kalina
Poland, Krakow
Jagiellonian University Medical College
M.c Mels, Catharina
South Africa, Potchefstroom
North-west University
Mokwatsi, Gontse Gratitude
South Africa, Potchefstroom
North-west University
Muxfeldt, Elizabeth Silaid
Brazil, Rio de Janeiro
Universidade Federal do Rio de Janeiro
Narkiewicz, Krzysztof
Poland, Gdansk
Gdanski Uniwersytet Medyczny
Odili, Augustine Nonso
Nigeria, Abuja
University of Abuja
Rajzer, Marek W.
Poland, Krakow
Jagiellonian University Medical College
Schutte, Aletta E.
South Africa, Potchefstroom
North-west University
Australia, Sydney
George Institute for Global Health
Stolarz-Skrzypek, Katarzyna
Poland, Krakow
Jagiellonian University Medical College
Tsai, Yiwen
Taiwan, Taipei
Taipei Veterans General Hospital
Vanassche, Thomas
Belgium, Leuven
Ku Leuven– University Hospital Leuven
Vanholder, Raymond Camille
Belgium, Brussels
European Kidney Health Alliance
Belgium, Ghent
Universitair Ziekenhuis Gent
Zhang, Zhenyu
Belgium, Leuven
Ku Leuven
Verhamme, Peter B.
Belgium, Leuven
Ku Leuven– University Hospital Leuven
Kruger, Ruan
South Africa, Potchefstroom
North-west University
Mischak, Harald
Germany, Hannover
Mosaiques-diagnostiques Gmbh
Staessen, Jan A.
Belgium, Mechelen
Research Institute Alliance for the Promotion of Preventive Medicine
Belgium, Leuven
Ku Leuven
Statistics
Citations: 8
Authors: 28
Affiliations: 19
Identifiers
Doi:
10.1080/08037051.2021.1952061
ISSN:
08037051
Research Areas
Disability
Health System And Policy
Noncommunicable Diseases
Study Design
Randomised Control Trial
Cohort Study